CD133-positive (CD133+) CSCs have demonstrated a capacity for unlimited self-renewal, as well as an ability to initiate and drive tumor progression in animal models (6,19), and a close correlation has been observed between the expression of CD133 and chemo-resistance and survival in gliomas (6,20,21). The gene discussed is PROM1; the disease is neoplasm.